Results 151 to 160 of about 104,820 (254)

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE‐042 China study

International Journal of Cancer, Volume 158, Issue 9, Page 2429-2439, 1 May 2026.
What's new? Global research has found that for people newly diagnosed with advanced non‐small cell lung cancer (NSCLC), the anti‐PD‐1 monoclonal antibody pembrolizumab on its own often leads to better results than traditional chemotherapy. The present report details long‐term findings of pembrolizumab therapy specifically among Chinese patients.
Yi‐Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Li Zhang, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Carmen González Arenas, Zhenghong Chen, Wen Cheng Yu, Tony S. K. Mok   +14 more
wiley   +1 more source

Knowledge and Intention to Practice Toward Mpox Among Iranian Healthcare Workers

Advances in Public Health
Aliasghar Fakhri-Demeshghieh, Ehsan Mostafavi, Amin Doosti-Irani, Mozhgan Ahmadinezhad, Farshid Rezaei, Behzad Amiri, Fahimeh Bagheri Amiri   +6 more
doaj   +1 more source

Raw Equid Milk: A Potential Risk for Q Fever? [PDF]

Animals (Basel)
Mazzotta E, Natale A, Bellinati L, Ceglie L, Lucchese L, Kevenk TO, Menandro ML, Giacometti F, Alberghini L.   +8 more
europepmc   +1 more source

Efficacy and safety of fruquintinib combined with albumin‐bound paclitaxel as second‐line therapy for advanced gastric cancer following failure of PD‐1 inhibitor‐containing treatment (TACTIC GC‐01): A phase II single‐arm study

International Journal of Cancer, Volume 158, Issue 9, Page 2219-2228, 1 May 2026.
What's new? Anti‐angiogenic drugs have shown promising efficacy as a second‐line treatment for advanced gastric cancer. However, it remains unclear how alterations in the tumor microenvironment following first‐line immunotherapy may impact tumor angiogenesis and influence subsequent therapeutic outcomes. This single‐arm study prospectively explored the
Xiaoting Ma, Kai Ou, Xiu Liu, Biyang Cao, Wenwei Yang, Jingyu Lu, Letian Zhang, Qi Wang, Lizhen Gao, Zhichao Jiang, Yongkun Sun, Lin Yang   +11 more
wiley   +1 more source

Prevalence and risk factors of neglected zoonoses in Ethiopian small ruminants: a focus on Q fever, brucellosis, chlamydiosis, and toxoplasmosis. [PDF]

One Health Outlook
Alemayehu G, Mamo G, Alemu B, Desta H, Tadesse B, Teshome D, Kumbe A, Wieland B, Knight-Jones T.   +8 more
europepmc   +1 more source

Infection Risk From Humans and Animals in the Anatomy Laboratory: A Scoping Review

Clinical Anatomy, Volume 39, Issue 3, Page 346-367, April 2026.
ABSTRACT Whole‐body dissection is a cornerstone of anatomy education. During and following the COVID‐19 pandemic, exposure to infectious agents and other risks of dissection were highlighted. To identify potential risks, one must have the data outlining these risks in specific situations.
Margaret A. McNulty, Elizabeth R. Agosto
wiley   +1 more source

An acute Q fever with vessel vasculitis: case report. [PDF]

Front Med (Lausanne)
Guo S, Liu Q, Yan J, Wang J, Zhong Y, Gao F, Zhong Y.   +6 more
europepmc   +1 more source

Treatment Outcomes With Novel Targeted and Immunotherapeutic Regimens in CAYA Hodgkin Lymphoma: A Retrospective Study

Cancer Innovation, Volume 5, Issue 2, April 2026.
Compared to conventional chemotherapy, treatment with BV‐AVD ± R in CAYA Hodgkin lymphoma patients resulted in comparable response rates (ORR: 96.4% vs. 95.4%) but with a marked reduction in Grade 4 hematologic toxicity (25.6% vs. 61.2%). BV‐AVD monotherapy yielded a higher ORR than BV‐AVD + R (100% vs. 93.9%).
Mengqing Xie, Meng Yuan, Mengwei Ren, Jing Tian, Shengyu Zhou, Xiaohui He, Yan Qin, Peng Liu, Jianliang Yang, Mengyuan Han, Fei Ma, Sheng Yang, Sidan Li   +12 more
wiley   +1 more source

Bicuspid Aortic Valve Endocarditis and Q Fever. [PDF]

JACC Case Rep
King SJ, Trinh KV, Kawana M.
europepmc   +1 more source

Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High‐Risk Recurrence Factors: A Phase II Single‐Center Prospective Study

Cancer Medicine, Volume 15, Issue 4, April 2026.
A phase II single‐center prospective study evaluating envafolimab combined with capecitabine and lenvatinib as postoperative adjuvant therapy in resected biliary tract cancer with high‐risk recurrence factors. The regimen demonstrated encouraging efficacy (median DFS 15.6 months; 1‐year DFS 68.3%; 1‐year OS 91.4%) and manageable safety, with no ...
Yitong Tian, Tian Lei, Qingyang Ruan, Xueying Zhou, Ruijing Shen, Tianao Xie, Shijie Li, Xiujun Cai, Mingyu Chen   +8 more
wiley   +1 more source